CordenPharma Increases U.S. Peptide Manufacturing Capacity

CordenPharma has expanded its peptide manufacturing capacity in CordenPharma Colorado, their GMP API facility in Boulder, Colorado. The expansion was done in order to accommodate for a large spike in demand for peptide API’s and to continue an overall growth strategy.

Dr. Matthieu Giraud, director, Global Peptides, Lipids & Carbohydrates Platform, explained, “With the addition of this extra-large 3’000 L SPPS vessel, our assembly-time, capacity and flexibility has been significantly increased, reinforcing CordenPharma Colorado as the current large-scale peptide manufacturing capacity leader. This new asset gives us the ability to manufacture a complex long peptide with a 400 kg output per single batch. Our team in Colorado aims to utilize this new capacity to conduct validation campaigns designed to support customer projects with a global impact.”

With approximately 300 employees, CordenPharma Colorado has a long track record in large-scale manufacturing, where all potencies, including picogram levels, can be reached.